Deep Braining...
TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF)
Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares
XASE:CANF
0.18
-26.44%

Ask
$0.58 - 200.00
Bid
$0.14 - 2,000.00
Low
$0.17
High
$0.2
Open
$0.2
Prev Close
$0.24
52W High
2.33
52W Low
0.17
Volume
3778528
Avg Vol (3m)
1299830.1
Float
4082780
Chart
TendieTensor AI Analysis

Company
Asset Type: American Depository Receipt Common
SIC Code:
Sector: Health Technology
Industry: Pharmaceuticals: Major
Date Listed: 09/10/2012
Primary Exchange: XASE

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

TendieTensor AI Analyst Recommendation:
Fundamentals
Total Employees:
5
P/E (TTM)
-0.100000
P/B (TTM)
0.569884
Round Lot
100
Composit FIGI
BBG003CMFDM2
Share Class FIGI
BBG003CMFFC8
Share Class Shares Outstanding
1.54M
Weighted Shares Outstanding
17.07M

Technicals
RSI (14)
MACD Line
MACD Signal
SMA 20
SMA 50
EMA 50
Trend
Short Interest
Days to Cover
Higher = harder to cover
Short Interest Δ
Prev: —
Short Volume Ratio (Today)
5D avg:
Squeeze Score (0–100)
Discussion
Login to participate in discussions.
Recent News
Related Stocks

Based on the portfolios of people who own CANF. This is a list generated by trading data from 3rd party trading platforms, and it's not a recommendation.